Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Korea’s Biopharma Regulatory Reform Push To Focus On Innovation, Streamlining

Multiple Areas Targeted

Executive Summary

South Korea is aiming to implement a broad range of regulatory reform steps to better compete with global rivals and speed up patient access to novel therapies.

You may also be interested in...



McKinsey Exec On Scaling The Rising Compliance Bar, Supply Chain Resilience

McKinsey & Company's senior partner Vikas Bhadoria, in this second instalment of a wide-ranging interview with Scrip, talks about 'smart quality', the compliance trajectory of Indian firms and also measures by Korea and China to accelerate biosimilar development and innovation.

Deal Watch: AbbVie Adds To Immunology Pipeline Through Deal With OSE

Plus deals involving Novo Nordisk/Neomorph, Mabwell/Jiangsu Haibo, Alteogen/Merck & Co., Gilead/Biocytogen, AlphaGen/ARTBIO and XOMA/Kinnate.

Doctors’ Protests Intensify In Korea As Essential Healthcare Challenges Highlighted

South Korea’s healthcare services face both longer-term systemic challenges and short-term disruption from ongoing doctor walkouts over government plans to boost medical trainees. Meanwhile, the local pharma industry is calling for new measures to support the supply of essential drugs.  

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147841

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel